Skin beautification with oral non-hydrolized versions of carnosine and carcinine: Effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging

Journal of Dermatological Treatment

Volumn 23, Issue 5, 2012, Pages 345-384

  Babizhayev, Mark A ^a,b,e   Deyev, Anatoliy I ^a   Savel'Yeva, Ekaterina L ^a   Lankin, Vadim Z ^c   Yegorov, Yegor E ^d  

^a Innovative Vision Products Incorporated   (United States)

^b MOSCOW HELMHOLTZ RESEARCH INSTITUTE OF EYE DISEASES   (Russian Federation)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^e Innovative Vision Products Inc   (Russian Federation)

Author keywords

a dicarbonyl compounds; advanced glycation Maillard reaction and lipoxidation end products; complications of diabetes and skin aging; imidazole containing dipeptides; Schiff bases' transglycating activities; skin care; superoxide anion radical production

Indexed keywords

1,2 DICARBONYL DERIVATIVE; ADVANCED GLYCATION END PRODUCT; AMINO ACID; CAN C PLUS; CARCININE; CARNOSINE; DIPEPTIDE DERIVATIVE; FREE RADICAL; METHYLGLYOXAL; SUPEROXIDE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; CUTANEOUS PARAMETERS; DIABETES MELLITUS; DRUG MECHANISM; ELECTRON SPIN RESONANCE; GLYCATION; HYDROLYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; SKIN CARE; SKIN SURFACE;

ADOLESCENT; ADULT; AGED; CARNOSINE; CERULOPLASMIN; DERMATOLOGIC AGENTS; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; FEMALE; FREE RADICALS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MIDDLE AGED; OXIDATIVE STRESS; PYRUVALDEHYDE; SCHIFF BASES; SKIN AGING; SKIN DISEASES; YOUNG ADULT;

EID: 84866303428     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2010.521812     Document Type: Article

References (141)

1. Cohen MP. Diabetes and protein glycation. New York: Springer-Verlag; 1986; 140 pp.
2. Sell DR, Monnier VM. Isolation, purification and partial characterization of novel fluorophores from aging human insoluble collagen-rich tissue. Connect Tissue Res. 1989; 19(1):77-92.
3. Dunn JA, Patrick JS, Thorpe SR, Baynes JW. Oxidation of glycated proteins: Age-dependent accumulation of Ne-(carboxymethyl) lysine in lens proteins. Biochemistry. 1989;28: 9464-9468. (Pubitemid 20000724)
4. Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW. Age-dependent accumulation of Ne-(carboxymethyl)lysine and Ne-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry. 1991;30:1205-1210.
5. Dyer DG, Blackledge JA, Katz BM, Hull CJ, Adkisson HD, Thorpe SR, et al. The Maillard reaction in vivo. Z Ernahrungswiss. 1991;30:29-45.
6. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix: Implication of pentoses in the aging process. J Biol Chem. 1989;264: 21597-21622.
7. Grandhee SK, Monnier VM.Mechanism of formation of the Maillard protein cross-link, pentosidine: Glucose, fructose and ascorbate as pentosidine precursors. J Biol Chem. 1991; 266:11 649-11 653. (Pubitemid 21906998)
8. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of protein by glucose: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem. 1991; 266:11 654-11 660. (Pubitemid 21906999)
9. Baynes JW. Perspectives in diabetes: Role of oxidative stress in development of complications in diabetes. Diabetes. 1991; 40:405-412.
10. Dunn JA, Ahmed MU, Murtiashaw MH, Richardson JM, Walla MD, Thorpe SR, et al. Reaction of ascorbate with lysine and protein under autoxidizing conditions: Formation of Ne-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry. 1990; 29:10 964-10 970.
11. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA. 1984;81:583-587. (Pubitemid 14186609)
12. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest. 1990;75:380-384. (Pubitemid 20070042)
13. Esterbauer H, Schuer RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehyde. Free Radic Biol Med. 1991;11:81-128. (Pubitemid 121003917)
14. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry. 1995;34:3702-3709.
15. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem. 1995;270: 10 017-10 026.
16. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J. 2003;375: 581-592. (Pubitemid 37433506)
17. Ames JM. Mass spectrometry to detect the site specificity of advanced glycation/lipoxidation end-product formation on protein: Some challenges and solutions. Biochem Soc Trans. 2008;36(Pt 5):1051-1054.
18. Pamplona R. Membrane phospholipids, lipoxidative damage and molecular integrity: A causal role in aging and longevity. Biochim Biophys Acta. 2008;1777(10):1249-1262.
19. Orlando G, Bengmark S. [Advanced glycation and lipoxidation end-products amplify inflammation. The role of a healthy diet.] Minerva Med. 2008;99(3):289-306. (Pubitemid 351929721)
20. Gil A, Bengmark S. [Advanced glycation and lipoxidation end products-amplifiers of inflammation: The role of food.] Nutr Hosp. 2007;22(6):625-640. (Pubitemid 350253994)
21. Stitt AW, Frizzell N, Thorpe SR. Advanced glycation and advanced lipoxidation: Possible role in initiation and progression of diabetic retinopathy. Curr Pharm Des. 2004;10 (27):3349-3360. (Pubitemid 39276621)
22. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J. 1987;245(1):243-250. (Pubitemid 17089839)
23. Harman D. The aging process. Proc Natl Acad Sci USA. 1981;78(11):7124- 7128.
24. Harman D. The free radical theory of aging: Effect of age on serum copper levels. J Gerontol. 1965;20:151-153.
25. Noto R, Alicata R, Sfogliano L, Neri S, Bifarella M. A study of cupremia in a group of elderly diabetics. Acta Diabetol Lat. 1983;20(1):81-85. (Pubitemid 13086297)
26. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs. 2001;10(11):1977-1987. (Pubitemid 33062221)
27. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 2001;44(1): 108-114. (Pubitemid 32141892)
28. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes. 2002;51(11):3283-3289. (Pubitemid 35246975)
29. Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem. 1997;272(9):5430-5437. (Pubitemid 27102361)
30. Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes. 2001; 109(6):330-336. (Pubitemid 32885036)
31. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem. 2000;275(28):21 177-21 184. (Pubitemid 30481811)
32. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes. 1997;46(5): 895-899. (Pubitemid 27188270)
33. Schwedler SB, Verbeke P, Bakala H, Weiss MF, Vilar J, Depreux P, et al. N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice. Diabetes Obes Metab. 2001;3(4):230-239. (Pubitemid 32785332)
34. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003;17 (12):1762-1764.
35. Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA. 2001; 98(3):1171-1175. (Pubitemid 32121205)
36. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A. Advanced glycation endproduct levels in subtotally nephrectomized rats: Beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab. 1999;25:380-383. (Pubitemid 30099695)
37. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol. 2002;13(10): 2478-2487.
38. Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy.] Ugeskr Laeger. 2001; 163(40):5514-5519. (Pubitemid 32927514)
39. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 2001;60 (1):228-234. (Pubitemid 32587558)
40. Severin SE. Problems concerned with the biological activity of naturally occurring imidazole compounds. Proceedings of the Plenary Session of the Seventh International Biochemical Congress, 1964, NY; pp. 45-61.
41. Boldyrev AA, Severin SE. The histidine-containing dipeptides, carnosine and anserine: Distribution, properties and biological significance. Adv Enzyme Regul. 1990;30:175-194.
42. Lenney JF. Specificity and distribution of mammalian carnosinase. Biochim Biophys Acta. 1976;429(1):214-219.
43. Jackson MC, Kucera CM, Lenney JF. Purification and properties of human serum carnosinase. Clin Chim Acta. 1991;196(2-3):193-205.
44. Lenney JF. Separation and characterization of two carnosine-splitting cytosolic dipeptidases from hog kidney (carnosinase and non-specific dipeptidase). Biol Chem Hoppe Seyler. 1990;371(5):433-440. (Pubitemid 20192429)
45. Kunze N, Kleinkauf H, Bauer K. Characterization of two carnosine-degrading enzymes from rat brain. Partial purification and characterization of a carnosinase and a beta-alanyl-arginine hydrolase. Eur J Biochem. 1986; 160(3):605-613. (Pubitemid 17044434)
46. Aldini G, Facino RM, Beretta G, Carini M. Carnosine and related dipeptides as quenchers of reactive carbonyl species: From structural studies to therapeutic perspectives. Biofactors. 2005;24(1-4):77-87. (Pubitemid 41750529)
47. Aldini G, Orioli M, Carini M, Maffei Facino R. Profiling histidine-containing dipeptides in rat tissues by liquid chromatography/ electrospray ionization tandem mass spectrometry. J Mass Spectrom. 2004;39(12):1417-1428. (Pubitemid 39664926)
48. Orioli M, Aldini G, Beretta G, Facino RM, Carini M. LCESI-MS/MS determination of 4-hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides as early markers of oxidative stress in excitable tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827(1):109-118. (Pubitemid 41551604)
49. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: A versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ. 2005;2005(18):pe12.
50. Rashid I, van Reyk DM, Davies MJ. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett. 2007;581(5):1067-1070.
51. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Kurysheva NI, et al. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides. 2001;22: 979-994. (Pubitemid 32522975)
52. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D. 2002;3(2):87-103. (Pubitemid 37062609)
53. Babizhayev MA, Deyev AI, Yermakova VN, Remenschikov VV, Bours J. Revival of the lens transparency with N-acetylcarnosine. Curr Drug Ther. 2006;1:91-116.
54. Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R D. 2004;5(3): 125-139. (Pubitemid 38780076)
55. Babizhayev MA. Method for topical treatment of eye disease and composition and device for said treatment. PCT Patent Application. International Publication Number WO 2004/028536 A1. International Publication Date: 8 April 2004.
56. Babizhayev MA. Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J Pharmacol Toxicol. 2006;1(3): 201-233.
57. Babizhayev MA. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res. 2004;7:186-198. (Pubitemid 39392265)
58. Babizhayev MA, Yermakova VN, Deyev AI, Seguin M-C. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J Anti Aging Med. 2000;3:43-62. (Pubitemid 30238692)
59. Arnould JM, Frentz R. Presence, isolation and chemical structure of a substance characteristic of cardiac tissue in Carcinus maenas (L.): Beta-alanylhistamine. Comp Biochem Physiol C. 1975;50(1):59-66.
60. Brotman DN, Flancbaum L, Fitzpatrick JC, Fisher H. Presence of carcinine (b-alanylhistamine) in mammalian tissues. FASEB J. 1989;3:1028.
61. Brotman DN, Flancbaum L, Kang YH, Merrill GF, Fisher H. Positive inotropic effects of carcinine in the isolated, perfused guinea pig heart. Crit Care Med. 1990;18: 317-321. (Pubitemid 20086864)
62. Flancbaum L, Brotman DN, Fitzpatrick JC, Van Es T, Kasziba E, Fisher H. Existence of carcinine, a histamine-related compound, in mammalian tissues. Life Sci. 1990;47: 1587-1593.
63. Ali SM, Tedford CE, Gregory R, Handley MK, Yates SL, Hirth WW, et al. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. J Med Chem. 1999;42:903-909. (Pubitemid 29136179)
64. Tedford CE, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, et al. Development of trans-2-[1Himidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J Pharmacol Exp Ther. 1999; 289:1160-1168. (Pubitemid 29191279)
65. Yates SL, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, et al. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. J Pharmacol Exp Ther. 1999;289(2):1151-1159. (Pubitemid 29191278)
66. Tozer MJ, Kalindjian SB. Histamine H3 receptor antagonists. Expert Opin Ther Pat. 2000;10:1045-1055.
67. Babizhayev MA. Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products. Life Sci. 2006;78(20):2343-2357.
68. Babizhayev MA, Seguin MC, Gueyne J, Evstigneeva RP, Ageyeva EA, Zheltukhina GA. L-carnosine (beta-alanyl-Lhistidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical- scavenging and lipid-peroxidase activities. Biochem J. 1994;304(Pt 2): 509-516. (Pubitemid 24368231)
69. Arnould JM, Frentz R. Carcinine (b-alanyl-histamine): Rapid synthesis and action on vertebrate blood pressure. Arch Int Physiol Biochim. 1977;85(2):339-350. (Pubitemid 8119216)
70. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004;3:115-124. (Pubitemid 38239773)
71. Wertz PW. Lipids and barrier function of the skin. Acta Derm Venereol Suppl (Stockh). 2000;208:7-11.
72. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, Baynes JW, et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J. 1997; 322(Pt 1):317-325.
73. Thornalley PJ. Monosaccharide autoxidation in health and disease. Environ Health Perspect. 1985;64:297-307. (Pubitemid 16135798)
74. Stewart JJP. MOPAC. F.J. Seiler Research Laboratory, Air Force Academy, Boulder, 1989. pp. 80840.
75. Stewart JJ. MOPAC ver 6., QCPE Bull., 1989;9:10. Revised as ver. 6.01 by T. Hirano, University of Tokyo, for HITAC and UNIX machines (JCPE Newsletter. 1989;1:10).
76. Babizhayev MA. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochimica et Biophysica Acta. 1989;1004:363-371. (Pubitemid 19216476)
77. Babizhayev MA, Bozzo Costa E. Lipid peroxide and reactive oxygen species generating systems of the crystalline lens. Biochimica et Biophysica Acta. 1994;1225:326-337. (Pubitemid 24066585)
78. Yoshikawa T, Naito Y, Tanigawa T, Yoneta T, Kondo M. The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-l- histidinato zinc. Biochim Biophys Acta. 1991;1115(1):15-22.
79. Iacazio G, Langrand G, Baratti J, Buono G, Triantaphylides CJ. Preparative, enzymatic synthesis of linoleic acid (13S)-hydroperoxide using soybean lipoxygenase-1. Organic Chemistry. 1993;55:1690.
80. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227:680-685.
81. Sammons DW, Adams LD, Nishizawa EE. Ultra sensitive silver based color staining of polypeptides in polyacrylamide gels. Electrophoresis. 1981;2:135.
82. Guiotto A, Ruzza P, Babizhayev MA, Calderan A. Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorg Med Chem. 2007;15(18):6158-6163. (Pubitemid 47088958)
83. Szwergold BS. Carnosine and anserine act as effective transglycating agents in decomposition of aldose-derived Schiff bases. Biochem Biophys Res Commun. 2005; 336(1):36-41. (Pubitemid 41253399)
84. Babizhayev MA, Meguro K. Combined use of carnosinase inhibitor with L-carnosines and composition. WO 2004/064866 PCT/JP2004/000351. Filed 20 January 2003 (20.01.2003).
85. Bando K, Shimotsuji T, Toyoshima H, Hayashi C, Miyai K. Fluorometric assay of human serum carnosinase activity in normal children, adults and patients with myopathy. Ann Clin Biochem. 1984;21(Pt 6):510-514. (Pubitemid 15223532)
86. Tronnier H, Wiebusch M, Heinrich U, Stute R. Surface evaluation of living skin. Adv Exp Med Biol. 1999;455: 507-516. (Pubitemid 32187502)
87. Tronnier H, Wiebusch M, Heinrich U, Stute R. Zur Bewertung der Oberflachenstruktur der Haut (SELS). Act Dermatol. 1997;23:290-295. (Pubitemid 27459925)
88. Khazaka G. Information and operating instructions for the Visioscan VC 98 and the software SELS 2000 (Surface Evaluation of the Living Skin). Cologne: CK Electronic; 2000.
89. Béguin A. A novel micronutrient supplement in skin aging: A randomized placebo-controlled double-blind study. J Cosmet Dermatol. 2005;4(4):277-284.
90. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids. 2003;25(3-4):275-281. (Pubitemid 38041265)
91. Bourajjaj M, Stehouwer CD, van Hinsbergh VW, Schalkwijk CG. Role of methylglyoxal adducts in the development of vascular complications in diabetes mellitus. Biochem Soc Trans. 2003;31(Pt 6):1400-1402. (Pubitemid 38030985)
92. Thornalley PJ. The glyoxalase system in health and disease. Mol Aspects Med. 1993;14(4):287-371.
93. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem. 1994;269(51):32 299-32 305.
94. Suji G, Sivakami S. DNA damage during glycation of lysine by methylglyoxal: Assessment of vitamins in preventing damage. Amino Acids. 2007;33(4):615-621. (Pubitemid 350165438)
95. Yim HS, Kang SO, Hah YC, Chock PB, Yim MB. Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. J Biol Chem. 1995;270(47): 28 228-28 233.
96. McLaughlin JA, Pethig R, Szent-Györgyi A. Spectroscopic studies of the protein-methylglyoxal adduct. Proc Natl Acad Sci USA. 1980;77(2):949-951. (Pubitemid 10108413)
97. Tarpey MM,Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: In vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol. 2004;286(3):R431-444. (Pubitemid 38252605)
98. Shumaev KB, Gubkina SA, Kumskova EM, Shepelkova GS, Ruuge EK, Lankin VZ. Superoxide formation as a result of interaction of L-lysine with dicarbonyl compounds and its possible mechanism. Biochemistry (Mosc). 2009;74(4): 461-466.
99. Bisby RH, Parker AW. Reactions of the alpha-tocopheroxyl radical in micellar solutions studied by nanosecond laser flash photolysis. FEBS Lett. 1991;290(1-2):205-208.
100. Aldini G, Carini M, Beretta G, Bradamante S, Facino RM. Carnosine is a quencher of 4-hydroxy-nonenal: Through what mechanism of reaction? Biochem Biophys Res Commun. 2002;298:699-706. (Pubitemid 35356796)
101. Pegova A, Abe H, Boldyrev A. Hydrolysis of carnosine and related compounds by mammalian carnosinases. Comp Biochem Physiol B Biochem Mol Biol. 2000;127: 443-446.
102. Babizhayev MA. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Drug Dev Ind Pharm. 2008;34(10):1071-1089.
103. Kang JH. Protective effects of carnosine and N-acetylcarnosine on salsolinol-mediated Cu,Zn-superoxide dismutase inactivation. Bull Korean Chem Soc. 2007;208(10): 1881-1884.
104. Neglia CI, Cohen HJ, Garber AR, Thorpe SR, Baynes JW. Characterization of glycated proteins by 13C NMR spectroscopy. Identification of specific sites of protein modification by glucose. J Biol Chem. 1985;260(9): 5406-5410. (Pubitemid 15003284)
105. Mossine VV, Glinsky GV, Feather MS. The preparation and characterization of some Amadori compounds (1-amino-1-deoxy-D-fructose derivatives) derived from a series of aliphatic omega-amino acids. Carbohydr Res. 1994;262(2): 257-270. (Pubitemid 24281592)
106. Babizhayev MA, Seguin M-C. Coupling product obtained from histamine and an amino acid. US Patent Number 5,792,784. Date of Patent 11 August 1998.
107. Babizhayev MA, Guiotto A, Kasus-Jacobi A. N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. J Drug Target. 2009;17(1): 36-63.
108. Conner JR, Beisswenger PJ, Szwergold BS. Some clues as to the regulation, expression, function, and distribution of fructosamine-3-kinase and fructosamine-3-kinase-related protein. Ann N Y Acad Sci. 2005;1043:824-836. (Pubitemid 41123977)
109. Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, Carreau A, et al. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem. 2003;278(8):6521-6531. (Pubitemid 36800914)
110. Unno H, Yamashita T, Ujita S, Okumura N, Otani H, Okumura A, et al. Structural basis for substrate recognition and hydrolysis by mouse carnosinase CN2. J Biol Chem. 2008;283(40):27 289-27 299.
111. Lee YT, Hsu CC, Lin MH, Liu KS, Yin MC. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol. 2005;513(1-2): 145-150.
112. Babizhayev MA. Current ocular drug delivery challenges for N-acetylcarnosine: Novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Recent Pat Drug Deliv Formul. 2009;3:229-265.
113. Wolff SP. The potential role of oxidative stress in diabetes and its complications: Novel implications for theory and therapy. In: Crabbe MJC, editor. Diabetic complications. New York: Churchill Livingstone; 1987. p. 167-220.
114. Godin DV, Wohaieb SA. Reactive oxygen radical processes in diabetes. In: Singal PK, editor. Oxygen radicals in the pathophysiology of heart disease. Boston: Kluwer Academic Publishers; 1988. p. 303-322.
115. Oberley LW. Free radicals and diabetes. Free Radic Biol Med. 1988;5:113-124. (Pubitemid 18263730)
116. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med. 1991;10:339-352. (Pubitemid 121003905)
117. VanderJagt DL, Robinson B, Taylor KK, Hunsaker LA. Reduction of trioses by NADPH-dependent aldo-keto reductases: Aldose reductase, methylglyoxal, and diabetic complications. J Biol Chem. 1992;267:4364-4369.
118. Jiang ZY, Woollard AC, Wolff SP. Hydrogen peroxide production during experimental protein glycation. FEBS Lett. 1990;268(1):69-71. (Pubitemid 20233832)
119. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J. 1988;256(1): 205-212.
120. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon- carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem. 1986; 261(11):4889-4894. (Pubitemid 17204276)
121. Hipkiss AR. Would carnosine or a carnivorous diet help suppress aging and associated pathologies? Ann N Y Acad Sci. 2006;1067:369-374. (Pubitemid 43806346)
122. Hipkiss AR. Carnosine, diabetes and Alzheimer's disease. Expert Rev Neurother. 2009;9(5):583-585.
123. Ukeda H, Hasegawa Y, Harada Y, Sawamura M. Effect of carnosine and related compounds on the inactivation of human Cu,Zn-superoxide dismutase by modification of fructose and glycolaldehyde. Biosci Biotechnol Biochem. 2002; 66(1):36-43. (Pubitemid 39251085)
124. Kang JH, Kim KS, Choi SY, Kwon HY, Won MH, Kang TC. Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu,Zn-superoxide dismutase modification. Biochim Biophys Acta. 2002; 1570:89-96. (Pubitemid 34457805)
125. Hipkiss AR, Preston JE, Himswoth DT, Worthington VC, Abbot NJ. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci Lett. 1997;238(3):135-138. (Pubitemid 28034341)
126. Hipkiss AR, Worthington VC, Himsworth DT, Herwig W. Protective effects of carnosine against protein modification mediated by malondialdehyde and hypochlorite. Biochim Biophys Acta. 1998;1380(1):46-54. (Pubitemid 28141020)
127. Zhou S, Decker EA. Ability of carnosine and other skeletal muscle components to quench unsaturated aldehydic lipid oxidation products. J Agric Food Chem. 1999;47(1): 51-55. (Pubitemid 29179622)
128. Aldini G, Granata P, Carini M. Detoxification of cytotoxic alpha,beta-unsaturated aldehydes by carnosine: Characterization of conjugated adducts by electrospray ionization tandem mass spectrometry and detection by liquid chromatography/mass spectrometry in rat skeletal muscle. J Mass Spectrom. 2002;37(12):1219-1228. (Pubitemid 36041609)
129. Hipkiss AR, Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun. 1998;248(1):28-32. (Pubitemid 28418181)
130. Hipkiss AR, Michaelis J, Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-proteincrosslinking agent. FEBS Lett. 1995;371(1):81-85.
131. Hipkiss AR, Michaelis J, Syrris P, Kumar S, Lam Y. Carnosine protects proteins against in vitro glycation and crosslinking. Biochem Soc Trans. 1994;22(4):399S. (Pubitemid 24373118)
132. Brownson C, Hipkiss AR. Carnosine reacts with a glycated protein. Free Radic Biol Med. 2000;28(10): 1564-1570. (Pubitemid 30604240)
133. Hobart LJ, Seibel I, Yeargans GS, Seidler NW. Anti-crosslinking properties of carnosine: Significance of histidine. Life Sci. 2004;75:1379-1389. (Pubitemid 38845036)
134. Hipkiss AR. Glycation, ageing and carnosine: Are carnivorous diets beneficial? Mech Ageing Dev. 2005;126(10): 1034-1039. (Pubitemid 41253854)
135. Seidler NW, Yeargans GS, Morgan TG. Carnosine disaggregates glycated alpha-crystallin: An in vitro study. Arch Biochem Biophys. 2004;427:110-115. (Pubitemid 38725919)
136. Yamagishi S-I, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev. 2005;1:93-106.
137. Hipkiss AR, Brownson C, Bertani MF, Ruiz E, Ferro A. Reaction of carnosine with aged proteins: Another protective process? Ann N Y Acad Sci. 2002;959:285-294. (Pubitemid 34457569)
138. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med. 2000;28: 1708-1716. (Pubitemid 30628657)
139. Babizhayev MA, Yegorov YE. Therapeutic uses of drug-carrier systems for imidazole-containing dipeptide compounds that act as pharmacological chaperones and have significant impact on the treatment of chronic diseases associated with increased oxidative stress and the formation of advanced glycation end products. Crit Rev Ther Drug Carrier Syst. 2010;27(2):85-154.
140. Babizhayev MA, Nikolayev GM, Nikolayeva JG, Yegorov YE. A survey and analysis of the role of molecular chaperone proteins and imidazole-containing dipeptide-based compounds as molecular escorts into the skin during stress, injury, water structuring and other types of cutaneous pathophysiology. Int J Cosmet Sci. Epub 2010 Jun 7.
141. Oturai PS, Christensen M, Rolin B, Pedersen KE, Mortensen SB, Boel E. Effects of advanced glycation endproduct inhibition and cross-link breakage in diabetic rats. Metabolism. 2000;49(8):996-1000. (Pubitemid 30641435)